1 ID ALD_HUMAN STANDARD; PRT; 745 AA.
3 DT 01-FEB-1994 (Rel. 28, Created)
4 DT 01-FEB-1994 (Rel. 28, Last sequence update)
5 DT 15-JUN-2004 (Rel. 44, Last annotation update)
6 DE Adrenoleukodystrophy protein (ALDP).
8 OS Homo sapiens (Human).
9 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
10 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
14 RX MEDLINE=93180910; PubMed=8441467;
15 RA Mosser J., Douar A.-M., Sarde C.-O., Kioschis P., Feil R., Moser H.,
16 RA Poustka A.-M., Mandel J.-L., Aubourg P.;
17 RT "Putative X-linked adrenoleukodystrophy gene shares unexpected
18 RT homology with ABC transporters.";
19 RL Nature 361:726-730(1993).
22 RA Platzer M., Bauer D., Brenner V., Drescher B., Nyakatura G.,
23 RA Reichwald K., Sandoval N., Coy J., Kioschis P., Korn B.,
24 RA Poustka A.-M., Rosenthal A.;
25 RL Submitted (MAY-1996) to the EMBL/GenBank/DDBJ databases.
27 RP SUBUNITS, AND CHARACTERIZATION OF VARIANTS X-ALD HIS-389; GLN-401;
28 RP ARG-484 AND GLN-591.
29 RX MEDLINE=20020240; PubMed=10551832;
30 RA Liu L.X., Janvier K., Berteaux-Lecellier V., Cartier N., Benarous R.,
32 RT "Homo- and heterodimerization of peroxisomal ATP-binding cassette
33 RT half-transporters.";
34 RL J. Biol. Chem. 274:32738-32743(1999).
36 RP FUNCTION, AND CHARACTERIZATION OF VARIANTS X-ALD SER-512 AND LEU-606.
37 RX MEDLINE=21145507; PubMed=11248239;
38 RA Roerig P., Mayerhofer P., Holzinger A., Gaertner J.;
39 RT "Characterization and functional analysis of the nucleotide binding
40 RT fold in human peroxisomal ATP binding cassette transporters.";
41 RL FEBS Lett. 492:66-72(2001).
44 RX MEDLINE=93283453; PubMed=8507690;
45 RA Aubourg P., Mosser J., Douar A.-M., Sarde C.-O., Lopez J.,
47 RT "Adrenoleukodystrophy gene: unexpected homology to a protein involved
48 RT in peroxisome biogenesis.";
49 RL Biochimie 75:293-302(1993).
51 RP REVIEW ON VARIANTS.
52 RX MEDLINE=97338663; PubMed=9195223;
53 RA Dodd A., Rowland S.A., Hawkes S.L.J., Kennedy M.A., Love D.R.;
54 RT "Mutations in the adrenoleukodystrophy gene.";
55 RL Hum. Mutat. 9:500-511(1997).
57 RP REVIEW ON VARIANTS.
58 RX MEDLINE=21614879; PubMed=11748843;
59 RA Kemp S., Pujol A., Waterham H.R., van Geel B.M., Boehm C.D.,
60 RA Raymond G.V., Cutting G.R., Wanders R.J.A., Moser H.W.;
61 RT "ABCD1 mutations and the X-linked adrenoleukodystrophy mutation
62 RT database: role in diagnosis and clinical correlations.";
63 RL Hum. Mutat. 18:499-515(2001).
65 RP VARIANT X-ALD LYS-291.
66 RX MEDLINE=94108454; PubMed=7904210;
67 RA Cartier N., Sarde C.-O., Douar A.-M., Mosser J., Mandel J.-L.,
69 RT "Abnormal messenger RNA expression and a missense mutation in
70 RT patients with X-linked adrenoleukodystrophy.";
71 RL Hum. Mol. Genet. 2:1949-1951(1993).
73 RP VARIANTS X-ALD SER-148; ASP-174; ARG-266; GLN-401; TRP-418 AND
75 RX MEDLINE=95152524; PubMed=7849723;
76 RA Fuchs S., Sarde C.-O., Wedemann H., Schwinger E., Mandel J.-L.,
78 RT "Missense mutations are frequent in the gene for X-chromosomal
79 RT adrenoleukodystrophy (ALD).";
80 RL Hum. Mol. Genet. 3:1903-1905(1994).
82 RP VARIANTS X-ALD TRP-518; LEU-606; CYS-617 AND HIS-617.
83 RX MEDLINE=94314951; PubMed=8040304;
84 RA Fanen P., Guidoux S., Sarde C.-O., Mandel J.-L., Goossens M.,
86 RT "Identification of mutations in the putative ATP-binding domain of
87 RT the adrenoleukodystrophy gene.";
88 RL J. Clin. Invest. 94:516-520(1994).
91 RX MEDLINE=95126139; PubMed=7825602;
92 RA Ligtenberg M.J.L., Kemp S., Sarde C.-O., van Geel B.M., Kleijer W.J.,
93 RA Barth P.G., Mandel J.-L., van Oost B.A., Bolhuis P.A.;
94 RT "Spectrum of mutations in the gene encoding the adrenoleukodystrophy
96 RL Am. J. Hum. Genet. 56:44-50(1995).
98 RP VARIANTS X-ALD HIS-104; GLU-178; LEU-560 AND GLY-528 DEL.
99 RX MEDLINE=95233433; PubMed=7717396;
100 RA Braun A., Ambach H., Kammerer S., Rolinski B., Stoeckler S., Rabl W.,
101 RA Gaertner J., Zierz S., Roscher A.A.;
102 RT "Mutations in the gene for X-linked adrenoleukodystrophy in patients
103 RT with different clinical phenotypes.";
104 RL Am. J. Hum. Genet. 56:854-861(1995).
107 RX MEDLINE=96047143; PubMed=7581394;
108 RA Kok F., Neumann S., Sarde C.-O., Zheng S., Wu K.-H., Wei H.-M.,
109 RA Bergin J., Watkins P.A., Gould S., Sack G., Moser H., Mandel J.-L.,
111 RT "Mutational analysis of patients with X-linked adrenoleukodystrophy.";
112 RL Hum. Mutat. 6:104-115(1995).
115 RX MEDLINE=96213748; PubMed=8651290;
116 RA Feigenbaum V., Lombard-Platet G., Guidoux S., Sarde C.-O.,
117 RA Mandel J.-L., Aubourg P.;
118 RT "Mutational and protein analysis of patients and heterozygous women
119 RT with X-linked adrenoleukodystrophy.";
120 RL Am. J. Hum. Genet. 58:1135-1144(1996).
123 RX MEDLINE=96163493; PubMed=8566952;
124 RA Krasemann E.W., Meier V., Korenke G.C., Hunneman D.H., Hanefeld F.;
125 RT "Identification of mutations in the ALD-gene of 20 families with
126 RT adrenoleukodystrophy/adrenomyeloneuropathy.";
127 RL Hum. Genet. 97:194-197(1996).
129 RP VARIANT X-ALD ARG-679.
130 RX MEDLINE=98112466; PubMed=9452087;
131 RA Korenke G.C., Krasemann E., Meier V., Beuche W., Hunneman D.H.,
133 RT "First missense mutation (W679R) in exon 10 of the
134 RT adrenoleukodystrophy gene in siblings with adrenomyeloneuropathy.";
135 RL Hum. Mutat. Suppl. 1:S204-S206(1998).
138 RX MEDLINE=99408241; PubMed=10480364;
139 RA Wichers M., Kohler W., Brennemann W., Boese V., Sokolowski P.,
140 RA Bidlingmaier F., Ludwig M.;
141 RT "X-linked adrenomyeloneuropathy associated with 14 novel ALD-gene
142 RT mutations: no correlation between type of mutation and age of onset.";
143 RL Hum. Genet. 105:116-119(1999).
145 RP VARIANTS X-ALD LEU-108 AND SER-143.
146 RX MEDLINE=99299442; PubMed=10369742;
147 RA Perusi C., Gomez-Lira M., Mottes M., Pignatti P.F., Bertini E.,
148 RA Cappa M., Vigliani M.C., Schiffer D., Rizzuto N., Salviati A.;
149 RT "Two novel missense mutations causing adrenoleukodystrophy in Italian
151 RL Mol. Cell. Probes 13:179-182(1999).
154 RX MEDLINE=20202141; PubMed=10737980;
155 RA Lachtermacher M.B., Seuanez H.N., Moser A.B., Moser H.W., Smith K.D.;
156 RT "Determination of 30 X-linked adrenoleukodystrophy mutations,
157 RT including 15 not previously described.";
158 RL Hum. Mutat. 15:348-353(2000).
160 RP VARIANTS X-ALD GLN-401; TRP-418; LEU-543 AND ARG-556.
161 RX MEDLINE=20438355; PubMed=10980539;
162 RA Lira M.G., Mottes M., Pignatti P.F., Medica I., Uziel G., Cappa M.,
163 RA Bertini E., Rizzuto N., Salviati A.;
164 RT "Detection of mutations in the ALD gene (ABCD1) in seven Italian
165 RT families: description of four novel mutations.";
166 RL Hum. Mutat. 16:271-271(2000).
168 RP VARIANTS X-ALD LEU-98; ASP-99; GLU-217; GLN-518; ASP-608; ILE-633 AND
169 RP PRO-660, AND VARIANT THR-13.
170 RX MEDLINE=21331689; PubMed=11438993;
171 RA Dvorakova L., Storkanova G., Unterrainer G., Hujova J., Kmoch S.,
172 RA Zeman J., Hrebicek M., Berger J.;
173 RT "Eight novel ABCD1 gene mutations and three polymorphisms in patients
174 RT with X-linked adrenoleukodystrophy: the first polymorphism causing an
175 RT amino acid exchange.";
176 RL Hum. Mutat. 18:52-60(2001).
178 RP VARIANT X-ALD VAL-GLY-GLN-300 INS.
179 RX MEDLINE=21668186; PubMed=11810273; DOI=10.1007/s00439-001-0632-z;
180 RA Guimaraes C.P., Lemos M., Menezes I., Coelho T., Sa-Miranda C.,
182 RT "Characterisation of two mutations in the ABCD1 gene leading to low
183 RT levels of normal ALDP.";
184 RL Hum. Genet. 109:616-622(2001).
186 RP INVOLVEMENT IN CONTIGUOUS ABCD1/DXS1375E DELETION SYNDROME.
188 RA Corzo D., Gibson W., Johnson K., Mitchell G., LePage G., Cox G.F.,
189 RA Casey R., Zeiss C., Tyson H., Cutting G.R., Raymond G.V., Smith K.D.,
190 RA Watkins P.A., Moser A.B., Moser H.W., Steinberg S.J.;
191 RT "Contiguous deletion of the X-linked adrenoleukodystrophy gene (ABCD1)
192 RT and DXS1357E: a novel neonatal phenotype similar to peroxisomal
193 RT biogenesis disorders.";
194 RL Am. J. Hum. Genet. 70:1520-1531(2002).
195 CC -!- FUNCTION: Probable transporter. The nucleotide-binding fold acts
196 CC as an ATP-binding subunit with ATPase activity.
197 CC -!- SUBUNIT: Can form homo- and heterodimers with ABCD2/ALDR and
198 CC ABCD3/PMP70. Dimerization is necessary to form an active
200 CC -!- SUBCELLULAR LOCATION: Integral membrane protein. Peroxisomal.
201 CC -!- DISEASE: Defects in ABCD1 are the cause of recessive X-linked
202 CC adrenoleukodystrophy (X-ALD) [MIM:300100]. X-ALD is a rare
203 CC peroxisomal metabolic disorder that occurs in boys and is
204 CC characterized by progressive multifocal demyelination of the
205 CC central nervous system and by adrenocortical insufficiency. It
206 CC produces mental deterioration, corticospinal tract dysfunction,
207 CC and cortical blindness. There is laboratory evidence of adrenal
208 CC cortical dysfunction. Different clinical manifestations exist
209 CC like: cerebral childhood ALD (CALD), adult cerebral ALD (ACALD),
210 CC adrenomyeloneuropathy (AMN) and "Addison disease only" (ADO)
212 CC -!- DISEASE: Microdeletions in ABCD1 are involved in the contiguous
213 CC ABCD1/DXS1375E deletion syndrome (CADDS) [MIM:300475]. Patients
214 CC manifest profound neonatal hypotonia, subsequent failure to
215 CC thrive, and cholestatic liver disease.
216 CC -!- SIMILARITY: Belongs to the ABC transporter family. ALD subfamily.
217 CC -!- DATABASE: NAME=X-ALD gene mutation database;
218 CC WWW="http://www.x-ald.nl/".
219 CC --------------------------------------------------------------------------
220 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
221 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
222 CC the European Bioinformatics Institute. There are no restrictions on its
223 CC use by non-profit institutions as long as its content is in no way
224 CC modified and this statement is not removed. Usage by and for commercial
225 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
226 CC or send an email to license@isb-sib.ch).
227 CC --------------------------------------------------------------------------
228 DR EMBL; Z21876; CAA79922.1; -.
229 DR EMBL; Z31348; CAA83230.1; -.
230 DR EMBL; Z31006; CAA83230.1; JOINED.
231 DR EMBL; Z31007; CAA83230.1; JOINED.
232 DR EMBL; Z31008; CAA83230.1; JOINED.
233 DR EMBL; Z31009; CAA83230.1; JOINED.
234 DR EMBL; Z31010; CAA83230.1; JOINED.
235 DR EMBL; U52111; -; NOT_ANNOTATED_CDS.
236 DR PIR; G02500; G02500.
237 DR Genew; HGNC:61; ABCD1.
241 DR GO; GO:0005779; C:integral to peroxisomal membrane; NAS.
242 DR GO; GO:0004009; F:ATP-binding cassette (ABC) transporter acti...; NAS.
243 DR GO; GO:0005215; F:transporter activity; NAS.
244 DR GO; GO:0015919; P:peroxisomal membrane transport; NAS.
245 DR GO; GO:0007031; P:peroxisome organization and biogenesis; NAS.
246 DR InterPro; IPR003593; AAA_ATPase.
247 DR InterPro; IPR003439; ABC_transporter.
248 DR InterPro; IPR005283; FA_transporter.
249 DR Pfam; PF00005; ABC_tran; 1.
250 DR Pfam; PF06472; Ald_N; 1.
251 DR ProDom; PD000006; ABC_transporter; 1.
252 DR TIGRFAMs; TIGR00954; 3a01203; 1.
253 DR PROSITE; PS50929; ABC_TM1F; 1.
254 DR PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
255 DR PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
256 KW ATP-binding; Glycoprotein; Transmembrane; Transport; Peroxisome;
257 KW Disease mutation; Polymorphism.
258 FT TRANSMEM 92 112 Potential.
259 FT TRANSMEM 131 151 Potential.
260 FT TRANSMEM 238 258 Potential.
261 FT TRANSMEM 333 353 Potential.
262 FT TRANSMEM 473 493 Potential.
263 FT NP_BIND 507 514 ATP (By similarity).
264 FT VARIANT 13 13 N -> T (very rare polymorphism; does not
265 FT affect ALDP function).
267 FT VARIANT 90 90 E -> K (in X-ALD).
269 FT VARIANT 98 98 S -> L (in X-ALD; CALD type).
271 FT VARIANT 99 99 A -> D (in X-ALD; AMN-type).
273 FT VARIANT 103 103 S -> R (in X-ALD).
275 FT VARIANT 104 104 R -> C (in X-ALD).
277 FT VARIANT 104 104 R -> H (in X-ALD; ADO-type).
279 FT VARIANT 105 105 T -> I (in X-ALD; ADO-type).
281 FT VARIANT 105 105 T -> P (in X-ALD).
283 FT VARIANT 107 107 L -> P (in X-ALD; ALD/AMN/ADO-types and
286 FT VARIANT 108 108 S -> L (in X-ALD).
288 FT VARIANT 108 108 S -> W (in X-ALD; CALD and AMN-types).
290 FT VARIANT 113 113 R -> C (in X-ALD).
292 FT VARIANT 113 113 R -> P (in X-ALD).
294 FT VARIANT 116 116 G -> R (in X-ALD; CALD-type).
296 FT VARIANT 123 123 A -> V.
298 FT VARIANT 138 141 Missing (in X-ALD; ALD-type).
300 FT VARIANT 141 141 A -> T (in X-ALD).
302 FT VARIANT 143 143 P -> S (in X-ALD).
304 FT VARIANT 148 148 N -> S (in X-ALD; ADO-type).
306 FT VARIANT 149 149 S -> N (in X-ALD).
308 FT VARIANT 152 152 R -> C (in X-ALD; ADO-type).
310 FT VARIANT 152 152 R -> L (in X-ALD).
312 FT VARIANT 152 152 R -> P (in X-ALD).
314 FT VARIANT 152 152 R -> S (in X-ALD).
316 FT VARIANT 161 161 S -> P (in X-ALD).
318 FT VARIANT 163 163 R -> H (in X-ALD).
320 FT VARIANT 163 163 R -> P (in X-ALD).
322 FT VARIANT 174 174 Y -> C (in X-ALD).
324 FT VARIANT 174 174 Y -> D (in X-ALD; ALD-type).
326 FT VARIANT 174 174 Y -> S (in X-ALD; CALD-type).
328 FT VARIANT 178 178 Q -> E (in X-ALD; AMN-type).
330 FT VARIANT 181 181 Y -> C (in X-ALD; ALMD-type).
332 FT VARIANT 182 182 R -> P (in X-ALD).
334 FT VARIANT 189 189 R -> W (in X-ALD).
336 FT VARIANT 190 190 L -> P (in X-ALD).
338 FT VARIANT 194 194 D -> H (in X-ALD).
340 FT VARIANT 198 198 T -> K (in X-ALD).
342 FT VARIANT 200 200 D -> N (in X-ALD).
344 FT VARIANT 200 200 D -> V (in X-ALD; CALD-type).
346 FT VARIANT 207 207 S -> SAAS (in X-ALD).
348 FT VARIANT 211 211 L -> P (in X-ALD).
350 FT VARIANT 213 213 S -> C (in X-ALD).
352 FT VARIANT 214 214 N -> D (in X-ALD).
354 FT VARIANT 217 217 K -> E (in X-ALD).
356 FT VARIANT 218 218 P -> T (in X-ALD).
358 FT VARIANT 220 220 L -> P (in X-ALD).
360 FT VARIANT 221 221 D -> G (in X-ALD; CALD and AMN-types).
362 FT VARIANT 224 224 V -> E (in X-ALD).
364 FT VARIANT 229 229 L -> P (in X-ALD).
366 FT VARIANT 254 254 T -> M (in X-ALD; AMN-type).
368 FT VARIANT 254 254 T -> P (in X-ALD; AMN-type).
370 FT VARIANT 263 263 P -> L (in X-ALD; CALD, AMN and AD-
373 FT VARIANT 266 266 G -> R (in X-ALD).
375 FT VARIANT 271 271 E -> K (in X-ALD).
377 FT VARIANT 274 274 R -> W (in X-ALD).
379 FT VARIANT 276 276 K -> E (in X-ALD; CALD-type).
381 FT VARIANT 277 277 G -> R (in X-ALD; AMN-type).
383 FT VARIANT 277 277 G -> GN (in X-ALD; ADO-type).
385 FT VARIANT 277 277 G -> W (in X-ALD).
387 FT VARIANT 280 280 R -> C (in X-ALD).
389 FT VARIANT 285 285 R -> P (in X-ALD).
391 FT VARIANT 291 291 E -> D (in X-ALD; ACALD and CALD-types).
393 FT VARIANT 291 291 E -> K (in X-ALD).
395 FT VARIANT 291 291 Missing (in X-ALD; ALD-type).
397 FT VARIANT 294 294 A -> T (in X-ALD; AMN-type).
399 FT VARIANT 296 296 Y -> C (in X-ALD).
401 FT VARIANT 298 298 G -> D (in X-ALD).
403 FT VARIANT 300 300 E -> EVGQ (in X-ALD).
405 FT VARIANT 302 302 E -> K (in X-ALD).
407 FT VARIANT 322 322 L -> P (in X-ALD).
409 FT VARIANT 336 336 K -> M (in X-ALD).
411 FT VARIANT 339 339 W -> R (in X-ALD).
413 FT VARIANT 342 342 S -> P (in X-ALD; AMN-type).
415 FT VARIANT 343 343 G -> D (in X-ALD).
417 FT VARIANT 389 389 R -> G (in X-ALD; AMN-type).
419 FT VARIANT 389 389 R -> H (in X-ALD; does not affect protein
420 FT stability, homo- and heterodimerization
421 FT with ALDR and PMP70).
423 FT VARIANT 401 401 R -> Q (in X-ALD; ALD and AMN-types; does
424 FT not affect protein stability, homo- and
425 FT heterodimerization with ALDR and PMP70).
427 FT VARIANT 401 401 R -> W (in X-ALD).
429 FT VARIANT 418 418 R -> W (in X-ALD; AMN-type).
431 FT VARIANT 427 427 Missing (in X-ALD).
433 FT VARIANT 484 484 P -> R (in X-ALD; CALD, AMN and ADO-
434 FT types; significantly decreases
435 FT homodimerization and abolishes
436 FT heterodimerization with ALDR and PMP70).
438 FT VARIANT 507 507 G -> V (in X-ALD; CALD-types).
440 FT VARIANT 512 512 G -> S (in X-ALD; CALD and AS-types;
441 FT reduced ATPase activity).
443 FT VARIANT 515 515 S -> F (in X-ALD).
445 FT VARIANT 518 518 R -> Q (in X-ALD; CALD-type).
447 FT VARIANT 518 518 R -> W (in X-ALD; CALD-type).
449 FT VARIANT 522 522 G -> W (in X-ALD; AD-type).
451 FT VARIANT 528 528 Missing (in X-ALD; CALD-type).
453 FT VARIANT 529 529 G -> S (in X-ALD).
455 FT VARIANT 534 534 P -> L (in X-ALD; CALD-type).
457 FT VARIANT 540 540 F -> S (in X-ALD).
459 FT VARIANT 543 543 P -> L (in X-ALD).
461 FT VARIANT 544 544 Q -> R (in X-ALD).
463 FT VARIANT 552 552 S -> P (in X-ALD).
465 FT VARIANT 554 554 R -> H (in X-ALD).
467 FT VARIANT 556 556 Q -> R (in X-ALD; ACALD type).
469 FT VARIANT 560 560 P -> L (in X-ALD; CALD-type).
471 FT VARIANT 560 560 P -> R (in X-ALD; AMN and ALMD-types).
473 FT VARIANT 560 560 P -> S (in X-ALD).
475 FT VARIANT 566 566 M -> K (in X-ALD).
477 FT VARIANT 591 591 R -> P (in X-ALD).
479 FT VARIANT 591 591 R -> Q (in X-ALD; AMN-type; significantly
480 FT decreases homodimerization and abolishes
481 FT heterodimerization with ALDR and PMP70).
483 FT VARIANT 591 591 R -> W (in X-ALD).
485 FT VARIANT 606 606 S -> L (in X-ALD; decreased ATP-binding
488 FT VARIANT 606 606 S -> P (in X-ALD; CALD, AMN and ALMD-
491 FT VARIANT 608 608 G -> D (in X-ALD; CALD-type).
493 FT VARIANT 609 609 E -> G (in X-ALD).
495 FT VARIANT 609 609 E -> K (in X-ALD; AMN-type).
497 FT VARIANT 616 616 A -> V (in X-ALD).
499 FT VARIANT 617 617 R -> C (in X-ALD; ALD-type and
502 FT VARIANT 617 617 R -> G (in X-ALD; ADO and AMN-types with
503 FT cerebral involvement).
505 FT VARIANT 617 617 R -> H (in X-ALD).
507 FT VARIANT 626 626 A -> D (in X-ALD).
509 FT VARIANT 626 626 A -> T (in X-ALD; CALD and AMN-types).
511 FT VARIANT 629 629 D -> H (in X-ALD).
513 FT VARIANT 630 630 E -> G (in X-ALD).
515 FT VARIANT 631 631 C -> Y (in X-ALD).
517 FT VARIANT 632 632 T -> I (in X-ALD).
519 FT VARIANT 633 633 S -> I (in X-ALD; asymptomatic).
521 FT VARIANT 633 633 S -> R (in X-ALD).
523 FT VARIANT 635 635 V -> M (in X-ALD).
525 FT VARIANT 636 636 S -> I (in X-ALD).
527 FT VARIANT 638 638 D -> Y (in X-ALD).
529 FT VARIANT 646 646 A -> P (in X-ALD).
531 FT VARIANT 654 654 L -> P (in X-ALD).
533 FT VARIANT 657 657 Missing (in X-ALD; CALD-type).
535 FT VARIANT 660 660 R -> P (in X-ALD; CALD-type).
537 FT VARIANT 660 660 R -> W (in X-ALD; CALD, ALMD and AS-
540 FT VARIANT 667 667 H -> D (in X-ALD).
542 FT VARIANT 668 668 T -> I (in X-ALD).
544 FT VARIANT 679 679 W -> R (in X-ALD; AMN-type).
546 FT VARIANT 693 693 T -> M (in X-ALD).
548 SQ SEQUENCE 745 AA; 82908 MW; 13A8EFDE9EB1E7FA CRC64;
549 MPVLSRPRPW RGNTLKRTAV LLALAAYGAH KVYPLVRQCL APARGLQAPA GEPTQEASGV
550 AAAKAGMNRV FLQRLLWLLR LLFPRVLCRE TGLLALHSAA LVSRTFLSVY VARLDGRLAR
551 CIARKDPRAF GWQLLQWLLI ALPATFVNSA IRYLEGQLAL SFRSRLVAHA YRLYFSQQTY
552 YRVSNMDGRL RNPDQSLTED VVAFAASVAH LYSNLTKPLL DVAVTSYTLL RAARSRGAGT
553 AWPSAIAGLV VFLTANVLRA FSPKFGELVA EEARRKGELR YMHSRVVANS EEIAFYGGHE
554 VELALLQRSY QDLASQINLI LLERLWYVML EQFLMKYVWS ASGLLMVAVP IITATGYSES
555 DAEAVKKAAL EKKEEELVSE RTEAFTIARN LLTAAADAIE RIMSSYKEVT ELAGYTARVH
556 EMFQVFEDVQ RCHFKRPREL EDAQAGSGTI GRSGVRVEGP LKIRGQVVDV EQGIICENIP
557 IVTPSGEVVV ASLNIRVEEG MHLLITGPNG CGKSSLFRIL GGLWPTYGGV LYKPPPQRMF
558 YIPQRPYMSV GSLRDQVIYP DSVEDMQRKG YSEQDLEAIL DVVHLHHILQ REGGWEAMCD
559 WKDVLSGGEK QRIGMARMFY HRPKYALLDE CTSAVSIDVE GKIFQAAKDA GIALLSITHR
560 PSLWKYHTHL LQFDGEGGWK FEKLDSAARL SLTEEKQRLE QQLAGIPKMQ RRLQELCQIL
561 GEAVAPAHVP APSPQGPGGL QGAST